FY2025 EPS Estimate for Arcus Biosciences Boosted by Analyst

Key Points

• Cantor Fitzgerald raised its FY2025 EPS estimate for Arcus Biosciences from ($4.52) to ($3.69), indicating a more optimistic outlook for the company's earnings.
• Institutional investors hold 92.89% of Arcus Biosciences stock, with significant recent increases in holdings by firms such as Gilead Sciences Inc. and Vanguard Group Inc..
• Despite a quarterly loss, Arcus Biosciences reported revenue of $160 million, significantly surpassing analyst estimates of $32.86 million, and achieving a year-over-year revenue increase of 310.3%.

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Investment analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for Arcus Biosciences in a research note issued on Thursday, August 7th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings per share of ($3.69) for the year, up from their prior forecast of ($4.52). The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.15) per share. Cantor Fitzgerald also issued estimates for Arcus Biosciences' FY2026 earnings at ($4.22) EPS.

A number of other analysts have also weighed in on RCUS. Wall Street Zen upgraded Arcus Biosciences from a "strong sell" rating to a "hold" rating in a research note on Saturday. Wedbush restated an "outperform" rating and set a $33.00 price target on shares of Arcus Biosciences in a research note on Wednesday, May 7th. The Goldman Sachs Group cut their price target on Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Morgan Stanley cut their price target on Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. Finally, Wells Fargo & Company cut their price target on Arcus Biosciences from $26.00 to $25.00 and set an "overweight" rating on the stock in a research note on Thursday, August 7th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $21.14.

Arcus Biosciences Trading Up 4.5%

RCUS stock traded up $0.44 during midday trading on Monday, reaching $10.11. The company's stock had a trading volume of 599,845 shares, compared to its average volume of 1,034,286. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.50 and a current ratio of 4.50. The stock has a fifty day simple moving average of $9.15 and a two-hundred day simple moving average of $9.39. Arcus Biosciences has a 1 year low of $6.50 and a 1 year high of $18.98. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of -3.20 and a beta of 0.89.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($1.11) earnings per share for the quarter, topping analysts' consensus estimates of ($1.14) by $0.03. Arcus Biosciences had a negative return on equity of 55.96% and a negative net margin of 109.56%. The business had revenue of $160.00 million for the quarter, compared to analyst estimates of $32.86 million. During the same quarter last year, the firm posted ($1.02) earnings per share. The business's revenue was up 310.3% compared to the same quarter last year.

Hedge Funds Weigh In On Arcus Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd purchased a new position in Arcus Biosciences in the second quarter valued at about $293,000. Ameritas Investment Partners Inc. grew its stake in Arcus Biosciences by 34.3% in the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company's stock valued at $57,000 after purchasing an additional 1,796 shares during the last quarter. Prudential Financial Inc. grew its stake in Arcus Biosciences by 6.5% in the second quarter. Prudential Financial Inc. now owns 70,010 shares of the company's stock valued at $570,000 after purchasing an additional 4,275 shares during the last quarter. Rhumbline Advisers grew its stake in Arcus Biosciences by 15.0% in the second quarter. Rhumbline Advisers now owns 210,355 shares of the company's stock valued at $1,712,000 after purchasing an additional 27,446 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Arcus Biosciences by 15.1% in the second quarter. JPMorgan Chase & Co. now owns 60,662 shares of the company's stock valued at $494,000 after purchasing an additional 7,943 shares during the last quarter. Hedge funds and other institutional investors own 92.89% of the company's stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.